BioLineRx in-licenses orally available peptide to treat obesity
World Disease Weekly - Aug. 15, 2006
BioLineRx, Ltd., has signed an exclusive worldwide licensing agreement with Yissum, the technology transfer company of the Hebrew University of Jerusalem, for the development and commercialization of BL-3020, a novel orally-available peptide for the treatment of obesity.
Financial terms of the license were not disclosed.
BL-3020 is a peptide that reduces food intake by binding to specific receptors in the brain that control appetite. In contrast to most peptide-based drugs, it has been made orally available through innovative modifications in its chemical structure. These modifications enable BL-3020 to cross the blood brain barrier, and increase its stability and absorption ...
Obesity Diet Pill Article